DE69529849T2 - Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion - Google Patents
Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretionInfo
- Publication number
- DE69529849T2 DE69529849T2 DE69529849T DE69529849T DE69529849T2 DE 69529849 T2 DE69529849 T2 DE 69529849T2 DE 69529849 T DE69529849 T DE 69529849T DE 69529849 T DE69529849 T DE 69529849T DE 69529849 T2 DE69529849 T2 DE 69529849T2
- Authority
- DE
- Germany
- Prior art keywords
- isochinolin
- bion
- apolipoprotein
- apo
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1995/000448 WO1996040640A1 (en) | 1995-06-07 | 1995-06-07 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69529849D1 DE69529849D1 (de) | 2003-04-10 |
DE69529849T2 true DE69529849T2 (de) | 2003-09-04 |
Family
ID=11004342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69529849T Expired - Fee Related DE69529849T2 (de) | 1995-06-07 | 1995-06-07 | Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion |
Country Status (20)
Country | Link |
---|---|
US (1) | US5919795A (de) |
KR (1) | KR100225713B1 (de) |
AR (1) | AR003424A1 (de) |
AT (1) | ATE233734T1 (de) |
AU (1) | AU703493B2 (de) |
BG (1) | BG62442B1 (de) |
CO (1) | CO4440626A1 (de) |
DE (1) | DE69529849T2 (de) |
DK (1) | DK0832069T3 (de) |
DZ (1) | DZ2045A1 (de) |
IL (3) | IL135376A (de) |
MA (1) | MA23895A1 (de) |
MX (1) | MX9709914A (de) |
OA (1) | OA10363A (de) |
RO (1) | RO116897B1 (de) |
RU (1) | RU2141478C1 (de) |
TN (1) | TNSN96085A1 (de) |
TR (1) | TR199600481A2 (de) |
TW (1) | TW476756B (de) |
YU (1) | YU35296A (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11507959A (ja) * | 1996-04-30 | 1999-07-13 | ファイザー インク. | 4’―トリフルオロメチルビフェニル―2―カルボン酸[2―(2h―[1,2,4]トリアゾール―3―イルメチル)―1,2,3,4―テトラヒドロ―イソキノリン―6―イル]―アミドを調製する方法及びそのための中間体 |
JP2959765B2 (ja) | 1997-12-12 | 1999-10-06 | 日本たばこ産業株式会社 | 3−ピペリジル−4−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物 |
CA2325358C (en) * | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b |
ES2240420T3 (es) * | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
US6953671B2 (en) * | 2001-02-23 | 2005-10-11 | The Trustees Of Columbia University In The City Of New York | Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action |
TNSN03146A1 (fr) * | 2001-06-28 | 2005-12-23 | Pfizer Prod Inc | Indoles, benzofurannes et benzothiophenes a substituant triamide, utiles comme inhibiteurs de secretion de la proteine de transfert des triglycerides microsomaux et/ou de l'apolipo-proteine b (apo b). |
US7241774B2 (en) * | 2002-03-13 | 2007-07-10 | University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
EP1689383B1 (de) | 2003-11-19 | 2012-10-31 | Metabasis Therapeutics, Inc. | Neue phosphor enthaltende thyromimetika |
WO2005051945A1 (en) * | 2003-11-20 | 2005-06-09 | Eli Lilly And Company | Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar |
AU2005214159A1 (en) * | 2004-02-04 | 2005-09-01 | Pfizer Products Inc. | Substituted quinoline compounds |
US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | 4−(2−メチルフェニル)ベンゾトリフルオライドの製造方法 |
US8980915B2 (en) * | 2005-04-19 | 2015-03-17 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion |
JP2008542255A (ja) * | 2005-05-27 | 2008-11-27 | ファイザー・プロダクツ・インク | 肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用 |
KR101407707B1 (ko) | 2006-04-03 | 2014-06-19 | 산타리스 팔마 에이/에스 | Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물 |
SG170773A1 (en) * | 2006-04-03 | 2011-05-30 | Santaris Pharma As | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
GB0619176D0 (en) * | 2006-09-29 | 2006-11-08 | Lectus Therapeutics Ltd | Ion channel modulators & uses thereof |
MX2009003729A (es) * | 2006-10-09 | 2009-04-22 | Santaris Pharma As | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. |
AR063275A1 (es) * | 2006-10-12 | 2009-01-14 | Epix Delaware Inc | Compuestos de carboxamida, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la activacion de ccr2. |
JP2010521193A (ja) * | 2007-03-22 | 2010-06-24 | サンタリス ファーマ アー/エス | Apo−b100発現の阻害のためのrnaアンタゴニスト化合物 |
WO2008113832A2 (en) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
WO2009027527A2 (en) * | 2007-08-30 | 2009-03-05 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of fabp4/ap2 |
EP2203559B1 (de) * | 2007-10-04 | 2014-02-26 | Stella ApS | Kombinationsbehandlung zur behandlung einer hepatitis-c-virusinfektion |
CN101925383A (zh) | 2007-12-11 | 2010-12-22 | 赛特帕斯凡德株式会社 | 甲酰胺化合物及其作为趋化因子受体激动剂的应用 |
US8404659B2 (en) * | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
CA2741153A1 (en) * | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
ES2599979T3 (es) * | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
US20100280067A1 (en) * | 2009-04-30 | 2010-11-04 | Pakala Kumara Savithru Sarma | Inhibitors of acetyl-coa carboxylase |
WO2010127208A1 (en) * | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
US20120122924A1 (en) * | 2010-11-15 | 2012-05-17 | Abbott Laboratories | Nampt inhibitors |
EP3591054A1 (de) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Gegen pcsk9 gerichtete antisense-oligomere und konjugate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
JPS5967246A (ja) * | 1982-09-10 | 1984-04-16 | ザ・ウエルカム・フアウンデ−シヨン・リミテツド | 置換ビフエニル化合物 |
GB9127306D0 (en) * | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US5731324A (en) * | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
IL110172A (en) * | 1993-07-22 | 2001-10-31 | Lilly Co Eli | Bicycle compounds and pharmaceuticals containing them |
CA2272719C (en) * | 1996-11-27 | 2002-10-01 | Pfizer Limited | Apo b-secretion/mtp inhibitory amides |
-
1995
- 1995-06-07 MX MX9709914A patent/MX9709914A/es not_active IP Right Cessation
- 1995-06-07 DK DK95918722T patent/DK0832069T3/da active
- 1995-06-07 US US08/952,507 patent/US5919795A/en not_active Expired - Fee Related
- 1995-06-07 DE DE69529849T patent/DE69529849T2/de not_active Expired - Fee Related
- 1995-06-07 AT AT95918722T patent/ATE233734T1/de not_active IP Right Cessation
-
1996
- 1996-04-19 TW TW085104696A patent/TW476756B/zh not_active IP Right Cessation
- 1996-05-30 IL IL13537696A patent/IL135376A/en not_active IP Right Cessation
- 1996-05-30 IL IL13537796A patent/IL135377A/en not_active IP Right Cessation
- 1996-05-30 IL IL13537596A patent/IL135375A/en not_active IP Right Cessation
- 1996-06-03 AR ARP960102871A patent/AR003424A1/es unknown
- 1996-06-05 DZ DZ960089A patent/DZ2045A1/fr active
- 1996-06-05 BG BG100637A patent/BG62442B1/bg unknown
- 1996-06-05 KR KR1019960020168A patent/KR100225713B1/ko not_active IP Right Cessation
- 1996-06-06 AU AU54784/96A patent/AU703493B2/en not_active Ceased
- 1996-06-06 TN TNTNSN96085A patent/TNSN96085A1/fr unknown
- 1996-06-06 RU RU96111018A patent/RU2141478C1/ru not_active IP Right Cessation
- 1996-06-06 YU YU35296A patent/YU35296A/sh unknown
- 1996-06-06 MA MA24265A patent/MA23895A1/fr unknown
- 1996-06-06 TR TR96/00481A patent/TR199600481A2/xx unknown
- 1996-06-07 RO RO96-01181A patent/RO116897B1/ro unknown
- 1996-06-07 OA OA60837A patent/OA10363A/en unknown
- 1996-06-07 CO CO96029732A patent/CO4440626A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA23895A1 (fr) | 1996-12-31 |
TR199600481A2 (tr) | 1996-12-21 |
BG100637A (bg) | 1997-03-31 |
MX9709914A (es) | 1998-03-31 |
US5919795A (en) | 1999-07-06 |
AU703493B2 (en) | 1999-03-25 |
RU2141478C1 (ru) | 1999-11-20 |
TNSN96085A1 (fr) | 2005-03-15 |
AU5478496A (en) | 1996-12-19 |
KR970003589A (ko) | 1997-01-28 |
IL135377A0 (en) | 2001-05-20 |
AR003424A1 (es) | 1998-08-05 |
DZ2045A1 (fr) | 2002-07-21 |
CO4440626A1 (es) | 1997-05-07 |
IL135376A0 (en) | 2001-05-20 |
IL135376A (en) | 2001-05-20 |
DE69529849D1 (de) | 2003-04-10 |
BG62442B1 (bg) | 1999-11-30 |
TW476756B (en) | 2002-02-21 |
ATE233734T1 (de) | 2003-03-15 |
IL135375A (en) | 2001-07-24 |
DK0832069T3 (da) | 2003-04-22 |
OA10363A (en) | 2001-11-15 |
KR100225713B1 (ko) | 1999-10-15 |
YU35296A (sh) | 1999-06-15 |
IL135377A (en) | 2001-05-20 |
IL135375A0 (en) | 2001-05-20 |
RO116897B1 (ro) | 2001-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69529849T2 (de) | Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion | |
FI974440A (fi) | Bifenyyli-2-karboksyylihappo-tetrahydro-isokinolin-6-yyli-amidijohdannaisia, niiden valmistus ja niiden käyttö mikrosomaalistatriglyseridiä siirtävän proteiinin ja/tai apolipoproteiini B:n (Apo B) erittymiseen inhibiittoreina | |
DE59913617D1 (de) | Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4. | |
DE122009000052I2 (de) | N-((1,2,4)triazoloazinyl)benzolsulfonamid- und pyridinsulfonamidverbindungen und deren verwendung als herbizide | |
DE69428025T2 (de) | Proteinkinase C-Inhibitoren | |
DE69435267D1 (de) | Proteinkinase C Inhibitoren | |
DE69833223D1 (de) | 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen | |
DE69627179T2 (de) | Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren | |
NO974453L (no) | Proteinkinase C-hemmere | |
ATE236165T1 (de) | Substituierte stickstoff enthaltende heterocyclen als p38 protein kinase inhibitoren | |
ATE277895T1 (de) | 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren | |
DE59703869D1 (de) | Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren | |
ATE214381T1 (de) | Thiazole derivate als protein kinase c inhibitoren | |
ATE224910T1 (de) | Derivate von dolestatin, deren herstellung und verwendung | |
DE69609199D1 (de) | Lacton derivate von 17.beta.-carboxy, carbothio und amide androstanverbindungen | |
DE69718791D1 (de) | Neuartige aminosäurederivate und deren verwendung als thrombininhibitoren | |
DE60009888D1 (de) | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen | |
DE69717647D1 (de) | 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen | |
DE69831950D1 (de) | Inhibitoren des hitzeschock-faktors | |
ATE343582T1 (de) | Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen | |
ATE253059T1 (de) | Substituierte 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2- one und ihre verwendung als lipase-hemmer | |
ATE209626T1 (de) | Alkyloxyamin-substituierte fluorenonderivate und ihre verwendung als proteinkinase-c-inhibitoren | |
DE69414194T2 (de) | Aminosäurederivate und ihre Verwendung als Enkephalinase-Inhibitoren | |
DE69623819D1 (de) | Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten | |
DE29717551U1 (de) | Beutelgebinde, Beutelgebindesortiment und Produktpalette von Beuteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |